Novel Agent Active in Refractory Polycythemia Vera

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.

In this video, John O. Mascarenhas, MD, of the Tisch Cancer Institute at Mount Sinai in New York, highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.

Mascarenhas presented results of the study (abstract 254) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Recent Videos
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content
Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

American Society for Transplantation and Cellular Therapy
October 30th 2024
Article

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy

Ashling Wahner
September 8th 2024
Article

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

FDA Approves Bortezomib Injection in Multiple Myeloma/MCL

Ariana Pelosci
September 6th 2024
Article

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

Treatment-Responsive Acute Graft-versus-Host Disease After Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes

Treatment-Responsive Acute Graft-versus-Host Disease After Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes

American Society for Transplantation and Cellular Therapy
August 30th 2024
Article

A recent study investigated the incidence and clinical outcomes of acute graft-versus-host disease following post-transplantation cyclophosphamide-based prophylaxis in hematopoietic cell transplantation.